ZA200101182B - Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases. - Google Patents

Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases. Download PDF

Info

Publication number
ZA200101182B
ZA200101182B ZA200101182A ZA200101182A ZA200101182B ZA 200101182 B ZA200101182 B ZA 200101182B ZA 200101182 A ZA200101182 A ZA 200101182A ZA 200101182 A ZA200101182 A ZA 200101182A ZA 200101182 B ZA200101182 B ZA 200101182B
Authority
ZA
South Africa
Prior art keywords
pyridyl
oxadiazine
dihydro
piperidinyl
methyl
Prior art date
Application number
ZA200101182A
Other languages
English (en)
Inventor
Andrea Jednakovits
Laszlo Ueroegdi
Denes Laszlo
Istvan Kurucz
Ede Marvanyos
Barabas
Mihaly
Ernoe Bacsy
Zsuzsanna Korom
Zoltan Nagy
Laszlo Uerge
Jenoe Szilbereky
Karoly Acsai
Peter Krajcsi
Zita Csakai
Magdolna Toeroek
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of ZA200101182B publication Critical patent/ZA200101182B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200101182A 1998-12-14 2001-02-12 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases. ZA200101182B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient

Publications (1)

Publication Number Publication Date
ZA200101182B true ZA200101182B (en) 2002-02-12

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200101182A ZA200101182B (en) 1998-12-14 2001-02-12 Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases.

Country Status (27)

Country Link
US (1) US6384029B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147105B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532498A (cg-RX-API-DMAC7.html)
KR (1) KR100661774B1 (cg-RX-API-DMAC7.html)
AT (1) ATE266027T1 (cg-RX-API-DMAC7.html)
AU (1) AU765336B2 (cg-RX-API-DMAC7.html)
BG (1) BG65179B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913982A (cg-RX-API-DMAC7.html)
CA (1) CA2340734C (cg-RX-API-DMAC7.html)
CZ (1) CZ300764B6 (cg-RX-API-DMAC7.html)
DE (1) DE69917074T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147105T3 (cg-RX-API-DMAC7.html)
EE (1) EE04551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2219091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010133B1 (cg-RX-API-DMAC7.html)
HU (1) HU226617B1 (cg-RX-API-DMAC7.html)
IL (1) IL141515A (cg-RX-API-DMAC7.html)
NO (1) NO317649B1 (cg-RX-API-DMAC7.html)
PL (1) PL196584B1 (cg-RX-API-DMAC7.html)
PT (1) PT1147105E (cg-RX-API-DMAC7.html)
RS (1) RS50129B (cg-RX-API-DMAC7.html)
RU (1) RU2222538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1147105T1 (cg-RX-API-DMAC7.html)
SK (1) SK285582B6 (cg-RX-API-DMAC7.html)
UA (1) UA70340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000035914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101182B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
DE69628320D1 (de) * 1995-11-03 2003-06-26 Summit Packaging Systems Ltd Vorrichtung zum abgeben und füllen von beuteln an einem kassenplatz eines supermarkts
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
IL141515A0 (en) 2002-03-10
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
DE69917074D1 (de) 2004-06-09
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
US6384029B1 (en) 2002-05-07
BG105342A (en) 2001-12-29
EE04551B1 (et) 2005-10-17
ES2219091T3 (es) 2004-11-16
HRP20010133B1 (en) 2005-02-28
CZ300764B6 (cs) 2009-08-05
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
CA2340734C (en) 2008-10-21
BR9913982A (pt) 2001-06-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
YU25001A (sh) 2004-07-15
HU226617B1 (en) 2009-04-28
PT1147105E (pt) 2004-07-30
KR100661774B1 (ko) 2006-12-28
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
JP5620340B2 (ja) 2014-11-05
JP2002532498A (ja) 2002-10-02
HRP20010133A2 (en) 2002-02-28
BG65179B1 (bg) 2007-05-31
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
SK285582B6 (sk) 2007-04-05
CA2340734A1 (en) 2000-06-22
PL346767A1 (en) 2002-02-25
IL141515A (en) 2005-09-25
AU1790600A (en) 2000-07-03
ATE266027T1 (de) 2004-05-15
KR20010073129A (ko) 2001-07-31
UA70340C2 (en) 2004-10-15
NO20012310L (no) 2001-05-10
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
NO20012310D0 (no) 2001-05-10
HUP9802897A2 (hu) 2000-11-28
EP1147105B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP5620340B2 (ja) 光学活性ピリジル−4h−1,2,4−オキサジアジン誘導体およびその血管疾患の治療における使用
JP2011201916A5 (cg-RX-API-DMAC7.html)
JP4316794B2 (ja) イソキノリン誘導体及び医薬
JPWO1999020620A1 (ja) イソキノリン誘導体及び医薬
JP3815691B2 (ja) プロペン酸誘導体
WO1997028130A1 (en) Isoquinoline derivatives and drugs
BR112012007828B1 (pt) compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase
TWI359016B (en) Heterocyclylacetic acids as inhibitors of tafia
JPH09100279A (ja) 抗真菌剤、その化合物及びその製造方法並びにその使用方法
JP4261639B2 (ja) フェニルイミダゾール系抗高脂血症薬
CN102603755B (zh) 一类具有协同氟康唑抗耐药真菌作用的化合物
IE921771A1 (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for¹their preparation and their use in medicaments
CN102775413A (zh) 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用
US5681843A (en) Parabanic acid derivatives
JP2657819B2 (ja) 強心三環式イミダゾロン類
JP3262800B2 (ja) 療用複素環化合物
JPH02149571A (ja) 強心アルカノイル及びアロイルオキサゾロン類
CN112759560B (zh) 含有n-氨基哌嗪片段的苯并噻嗪-4-酮类化合物及其制备方法
CN108774220A (zh) 用于治疗心肌缺血的化合物及其应用
JP3589817B2 (ja) 抗真菌剤
JPH02288864A (ja) 4(1h)キノロン誘導体
JPH0770083A (ja) イミダゾール誘導体を有効成分とする血圧降下剤
CN101684099A (zh) 取代芳香环、芳香杂环的丙酸衍生物、其制备方法和用途
JP2002527440A (ja) イミダゾ−イソキノリン化合物、その組成物、および使用